TCRX
Tscan Therapeutics Inc
0.364$
+2.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 33.1% | 17.8% | 221.6% | 208.2% | 97.9% | 106.9% | – | – | 30.5% | 28.2% | 70.6% | – | – | |
| 100.0% | 82.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 29.4% | 100.0% | 90.3% | |
| 585.1% | 310.7% | 4,391.7% | 5,014.4% | 2,503.5% | 4,414.1% | 1,372.1% | 1,060.9% | 1,262.0% | 780.6% | 2,230.5% | 2,226.6% | 1,364.6% | |
| 151.6% | 85.5% | 1,219.4% | 1,416.0% | 706.3% | 1,097.0% | 389.5% | 290.0% | 306.6% | 223.2% | 836.8% | 774.7% | 418.9% | |
| 736.7% | 378.4% | 5,642.9% | 6,464.6% | 3,209.8% | 5,620.6% | 1,769.7% | 1,356.6% | 1,575.6% | 1,029.4% | 2,996.7% | 3,001.3% | 1,785.4% | |
| -636.7% | -296.2% | -5,542.9% | -6,364.6% | -3,109.8% | -5,520.6% | -1,669.7% | -1,256.6% | -1,475.6% | -929.4% | -2,967.3% | -2,901.3% | -1,695.1% | |
| 25.3% | 11.8% | 169.4% | 177.6% | 91.3% | 117.9% | 31.3% | 22.4% | 27.8% | 27.3% | 70.2% | 66.5% | 39.2% | |
| -591.6% | -272.0% | -5,325.4% | -5,906.9% | -2,849.1% | -5,384.8% | -1,571.9% | -1,201.3% | -1,422.1% | -895.1% | -2,919.1% | -2,888.6% | -1,655.4% | |
| -33.1% | -14.2% | -221.6% | -208.2% | – | 188.6% | – | – | – | – | – | – | – | |
| -591.6% | -272.0% | -5,325.4% | -5,906.9% | -2,849.1% | -5,384.8% | -1,571.9% | -1,201.3% | -1,422.1% | -895.1% | -2,919.1% | -2,888.6% | -1,655.4% | |
| -533.3% | -242.4% | -4,934.5% | -5,521.1% | -2,659.9% | -5,160.0% | -1,509.4% | -1,156.2% | -1,363.8% | -839.6% | -2,778.4% | -2,755.6% | -1,575.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.